Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Lannett Company, Inc. Enters Into Restructuring Support Agreement PR Newswire TREVOSE, Pa., May 1, 2023 Restructuring Support Agreement Supported by Holders of More Than 80% of the Company's...
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS PR Newswire TREVOSE, Pa., April 20, 2023 Company Expects No Impact on Operations Negotiations...
LANNETT SHARES UPDATE PR Newswire TREVOSE, Pa., April 4, 2023 Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive...
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE PR Newswire TREVOSE, Pa., Feb. 1, 2023 Q2 Business and Financial Highlights: Net Sales were $80.9...
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT PR Newswire TREVOSE, Pa., Jan. 25, 2023 TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its Board...
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 PR Newswire TREVOSE, Pa., Jan. 25, 2023 TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/...
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS PR Newswire TREVOSE, Pa., Jan. 4, 2023 --Announces Positive Animal PK Study Results of Insulin Aspart Versus US...
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM PR Newswire TREVOSE, Pa., Nov. 7, 2022 TREVOSE...
LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE PR Newswire TREVOSE, Pa., Nov. 2, 2022 Q1 Business and Financial...
LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2 PR Newswire TREVOSE, Pa., Oct. 26, 2022 TREVOSE, Pa., Oct. 26, 2022 /PRNewswire/...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
